论文部分内容阅读
作者用~(131)I标记的UJ13A对患Ⅳ期神经母细胞和原发脑瘤的儿童进行研究。标记物研究的放射性计量资料表明在易损器官和肿瘤间的放射剂量有很大差异。肝平均剂量为2.97rad/mci±1.85 SD,脾平均剂量为8.9rad±5.28SD,进入全身血液的平均剂量为0.57rad±5.28SD,进入全身血液的平均剂量为0.57rad/mci±0.29SD,肿瘤部位平均剂量为37.5rad/mci±23.00SD。输注抗体放射治疗的毒性反应是轻微的和自限性的。仅一名患者发生了过敏反应。皮肤试验不能预测这一反应。主要的毒性反应是骨髓发育不良。这发生在接受55mci,~(131)I-UJ13A和全身剂量为0.88和1.3rad/mci的两名儿童中。而全身剂量分别为0.55和0.77rad/mci的另两名儿童却未见这一毒性反应。受治的5
The authors studied children with stage IV neuroblastomas and primary brain tumors using ~(131)I-labeled UJ13A. The radiometric data from the marker studies showed a large difference in radiation doses between vulnerable organs and tumors. The average liver dose was 2.97 rad/mci ± 1.85 SD, the average spleen dose was 8.9 rad ± 5.28 SD, the average dose into the systemic blood was 0.57 rad ± 5.28 SD, and the average dose into the systemic blood was 0.57 rad/mci ± 0.29 SD. The average tumor site dose was 37.5 rad/mci ± 23.00 SD. The toxicity of infused antibody to radiation therapy is slight and self-limiting. Only one patient had an allergic reaction. Skin tests cannot predict this reaction. The main toxic reaction is myelodysplasia. This occurred in two children receiving 55mci, ~(131)I-UJ13A and whole body doses of 0.88 and 1.3 rad/mci. The other two children with systemic doses of 0.55 and 0.77 rad/mci did not have this toxic reaction. Treated 5